Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents
Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, Olivero RM, Oliveira CR, James SH, Morton TH, Maron GM, Young JL, Orscheln RC, Schwenk HT, Bio LL, Willis ZI, Lloyd EC, Hersh AL, Huskins CW, Soma VL, Ratner AJ, Hayes M, Downes K, Chiotos K, Grapentine SP, Wattier RL, Lamb GS, Zachariah P, Nakamura MM. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Journal Of The Pediatric Infectious Diseases Society 2022, 11: 177-185. PMID: 35107571, PMCID: PMC8903349, DOI: 10.1093/jpids/piab124.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyPediatric infectious diseasesAntibody therapyEmergency use authorizationSevere diseasePostexposure prophylaxisHigh riskCOVID-19Severe acute respiratory syndrome coronavirus 2Certain high-risk conditionsSpecific monoclonal antibody therapyAcute respiratory syndrome coronavirus 2Infectious diseasesRespiratory syndrome coronavirus 2Moderate COVID-19Pediatric critical care medicineSyndrome coronavirus 2Coronavirus disease 2019Critical care medicineHigh-risk conditionsSeries of teleconferencesHigh-risk exposureBamlanivimab monotherapyInfusion reactionsControlled Trials